Selskabets formål er at fremme kommercialiseringen af nye idéer og forskningsresultater og start af nye innovative virksomheder gennem drift af forskerpark og inkubator, rådgivningsvirksomhed samt al virksomhed, som efter bestyrelsens skøn er beslægtet hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 31.1 mio. | -3.7 mio. | 50.9 mio. | 21.6 mio. | 1 | |
CVR: 28870523
Secondary names: COPENHAGEN BIO SCIENCE PARK A/S, Cobis A/S
Previous names: KR 433 A/S, COBIS A/S
Compared to 18.647 companies in Udlejning af erhvervsejendomme
Comparison is based on industry median values
Morten Frederiksen joined the board
Søren Hvidkjær left the board
The financial health of Symbion Frederiksberg A/S shows signs of volatility, particularly with a significant loss in 2024, where the company reported a profit of -3,683,952 DKK despite a revenue increase to 31,064,434 DKK. Over the past few years, revenue has fluctuated, peaking at 36,372,864 DKK in 2020 but declining to 23,794,728 DKK in 2023 before a slight recovery in 2024. The equity position remains relatively strong at 21,580,200 DKK, though it has decreased from previous years, indicating potential concerns regarding profitability and operational efficiency. Overall, the company operates within the commercial real estate rental sector, where it faces challenges in maintaining consistent profitability and managing its equity effectively.
AI-generated summary
Companies in the same industry and area
companydata.dk